SMN2
Survival motor neuron protein
As of the edition of 20 October 2026, SMN2 (survival motor neuron protein, UniProt Q16637) has 2 drugs tested at it and 2 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q16637
- How well studied
- Chemical tools exist; no approved drug acts on it
- Solved structures
- 16
- Disease areas
- Nervous system; Inherited and neonatal; Nutrition and metabolism
- Registered trials of its drugs
- 48
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Nusinersen | Marketed | Phase 4 | Ends 2030 |
| Risdiplam | Marketed | Phase 4 | Ends 2041 |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Total on the list | 2 |
The other 0 companies at SMN2
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at SMN2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.